<DOC>
	<DOCNO>NCT00713401</DOCNO>
	<brief_summary>Assess tolerability safety rapid bolus tecadenoson different dose level give alone combination beta-blocker ( esmolol ) patient atrial fibrillation control rapid heart rate . Explore pharmacokinetic pharmacodynamic effect give alone combination beta-blocker ( esmolol ) .</brief_summary>
	<brief_title>Safety Study Tecadenoson Treat Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<mesh_term>Tecadenoson</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Have diagnosis atrial fibrillation need treatment rate control Be able willing abstain antiarrhythmic , include atrioventricular ( AV ) nodal block agent ( except esmolol per protocol ) , later 8:00 p.m. day prior dose completion last dose period assessment Be able willing abstain xanthine chocolatecontaining food , beverage , medication Females must postmenopausal sterilize ; childbearing potential , must breastfeed must negative pregnancy test screen intention become pregnant course study . Males females must use adequate contraception study . Have know accessory pathway Have active myocardial ischemia recent acute coronary syndrome Have acute overt heart failure , bradycardia , heart block great first degree , cardiogenic shock Have allergy contraindication treatment esmolol aminophylline , constituent Have supine cuff systolic blood pressure &lt; 90 mm Hg Be undergo treatment theophylline/aminophylline preparation , TrentalÂ® ( pentoxifylline ) , carbamazepine Have asthma reactive airway disease currently ontreatment Have history active chronic pancreatic disease clinically significant increase level serum amylase lipase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>